hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 13:26:10 - browse：3949

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Physicians and social media: If you see something, say something?

Wikipedia

WSS

Acelyrin, a rare IPO success, stumbles in its first big test

Gene editing the human germline: What are the risks?

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Regeneron agrees to White House price limits on anti

Readout Newsletter: Bluebird, CVS, Contineum

Neuroscience’s long legacy of racism

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

Malaria cases in Florida and Texas: Here’s what you need to know

PEPFAR is under serious threat — and so is global health

The high cost of giving birth even with insurance

White House touts steps to stem shortages of cancer treatments

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Nurses recount patients attacks

Malaria cases in Florida and Texas: Here’s what you need to know

FDA approves updated Covid vaccines

As demand for Covid shots wanes, Moderna seeks its next success

Private equity could exacerbate cardiology's overuse problem, experts fear

focus

Creating egg and sperm cells from stem cells raises ethical issues

Virtual Event: March of the Biosimilars

PEPFAR is under serious threat — and so is global health

Health AI adoption puts security, privacy startups on investors' radar

Neuroscience’s long legacy of racism

Readout Newsletter: Bluebird, CVS, Contineum

Wikipedia

hotspot

leisure time

focus